HPS Pharmacies wish to give notice that Pfizer is experiencing a supply interruption for sulfamethoxazole + trimethoprim ampoules as follows:
DBL™ Sulfamethoxazole 400mg and Trimethoprim 80mg Concentrate Injection BP
Sulfamethoxazole + trimethoprim 400mg+80mg/5mL
Normal supplies are expected to resume in late April 2020. An internationally registered brand of sulfamethoxazole + trimethoprim ampoules has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. The packaging for this product is in the German language. Please refer to the Australian product information for DBL™ Sulfamethoxazole 400mg and Trimethoprim 80mg Concentrate Injection for further information when using this product.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates